These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials. Martini G; Ciardiello D; Famiglietti V; Rossini D; Antoniotti C; Troiani T; Napolitano S; Esposito L; Latiano TP; Maiello E; Del Re M; Lonardi S; Aprile G; Santini D; Masi G; Avallone A; Normanno N; Pietrantonio F; Pinto C; Ciardiello F; Cremolini C; Martinelli E Cancer Med; 2023 Apr; 12(8):9392-9400. PubMed ID: 36880426 [TBL] [Abstract][Full Text] [Related]
5. Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial. Napolitano S; Ciardiello D; De Falco V; Martini G; Martinelli E; Della Corte CM; Esposito L; Famiglietti V; Di Liello A; Avallone A; Cardone C; De Stefano A; Montesarchio V; Zampino MG; Fazio N; Di Maio M; Del Tufo S; De Vita F; Altucci L; Marrone F; Ciardiello F; Troiani T Int J Cancer; 2023 Oct; 153(8):1520-1528. PubMed ID: 37391938 [TBL] [Abstract][Full Text] [Related]
6. Rechallenge with Anti-EGFR Treatment in RAS/BRAF wt Metastatic Colorectal Cancer (mCRC) in Real Clinical Practice: Experience of the GITuD Group. Salgado Fernández M; Reboredo López M; Covela Rúa M; Candamio S; González-Villarroel P; Sánchez-Cousido LF; Graña B; Carral-Maseda A; Cameselle-García S; Varela Pose V; Gallardo-Martín ME; Martínez-Lago N; Target Oncol; 2024 Jul; 19(4):565-573. PubMed ID: 38780742 [TBL] [Abstract][Full Text] [Related]
7. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial. Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968 [TBL] [Abstract][Full Text] [Related]
8. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. Ciardiello D; Famiglietti V; Napolitano S; Esposito L; Pietrantonio F; Avallone A; Maiello E; Cremolini C; Troiani T; Martinelli E; Ciardiello F; Martini G Clin Colorectal Cancer; 2022 Jun; 21(2):141-148. PubMed ID: 35101346 [TBL] [Abstract][Full Text] [Related]
9. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. Nakajima H; Kotani D; Bando H; Kato T; Oki E; Shinozaki E; Sunakawa Y; Yamazaki K; Yuki S; Nakamura Y; Yamanaka T; Yoshino T; Ohta T; Taniguchi H; Kagawa Y BMC Cancer; 2021 Jun; 21(1):674. PubMed ID: 34098908 [TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study. Yang L; Zhang W; Fan N; Cao P; Cheng Y; Zhu L; Luo S; Zong H; Bai Y; Zhou J; Deng Y; Ba Y; Liu T; Aili M; Yin X; Gu K; Dai G; Ying J; Shi J; Gao Y; Li W; Yu G; Xie L; Gai W; Wang Y; Meng P; Shi Y EBioMedicine; 2024 Feb; 100():104966. PubMed ID: 38217945 [TBL] [Abstract][Full Text] [Related]
11. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer. Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883 [TBL] [Abstract][Full Text] [Related]
12. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403 [TBL] [Abstract][Full Text] [Related]
13. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Sartore-Bianchi A; Pietrantonio F; Lonardi S; Mussolin B; Rua F; Crisafulli G; Bartolini A; Fenocchio E; Amatu A; Manca P; Bergamo F; Tosi F; Mauri G; Ambrosini M; Daniel F; Torri V; Vanzulli A; Regge D; Cappello G; Marchiò C; Berrino E; Sapino A; Marsoni S; Siena S; Bardelli A Nat Med; 2022 Aug; 28(8):1612-1618. PubMed ID: 35915157 [TBL] [Abstract][Full Text] [Related]
14. A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial. Izawa N; Masuishi T; Takahashi N; Shoji H; Yamamoto Y; Matsumoto T; Sugiyama K; Kajiwara T; Kawakami K; Aomatsu N; Kondoh C; Kawakami H; Takegawa N; Esaki T; Shimokawa M; Nishio K; Narita Y; Hara H; Sunakawa Y; Boku N; Moriwaki T; Eguchi Nakajima T; Muro K Target Oncol; 2023 May; 18(3):369-381. PubMed ID: 37148491 [TBL] [Abstract][Full Text] [Related]
15. Negative Hyperselection of Patients With Morano F; Corallo S; Lonardi S; Raimondi A; Cremolini C; Rimassa L; Murialdo R; Zaniboni A; Sartore-Bianchi A; Tomasello G; Racca P; Clavarezza M; Adamo V; Perrone F; Gloghini A; Tamborini E; Busico A; Martinetti A; Palermo F; Loupakis F; Milione M; Fucà G; Di Bartolomeo M; de Braud F; Pietrantonio F J Clin Oncol; 2019 Nov; 37(33):3099-3110. PubMed ID: 31539295 [TBL] [Abstract][Full Text] [Related]
16. Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer. Sommerhäuser G; Kurreck A; Stintzing S; Heinemann V; von Weikersthal LF; Dechow T; Kaiser F; Karthaus M; Schwaner I; Fuchs M; König A; Roderburg C; Hoyer I; Quante M; Kiani A; Fruehauf S; Müller L; Reinacher-Schick A; Ettrich TJ; Stahler A; Modest DP BMC Cancer; 2022 Jul; 22(1):820. PubMed ID: 35897060 [TBL] [Abstract][Full Text] [Related]
17. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682 [TBL] [Abstract][Full Text] [Related]
18. Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients. Moretto R; Rossini D; Capone I; Boccaccino A; Perrone F; Tamborini E; Masi G; Antoniotti C; Marmorino F; Conca V; Borelli B; Martignetti A; Pecora I; Simionato F; Cupini S; Ambrosini M; Manca P; Pietrantonio F; Falcone A; Cremolini C Clin Colorectal Cancer; 2021 Dec; 20(4):314-317. PubMed ID: 34364814 [TBL] [Abstract][Full Text] [Related]
19. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review. Ciardiello D; Mauri G; Sartore-Bianchi A; Siena S; Zampino MG; Fazio N; Cervantes A Cancer Treat Rev; 2024 Mar; 124():102683. PubMed ID: 38237253 [TBL] [Abstract][Full Text] [Related]
20. China special issue on gastrointestinal tumors-Cetuximab retreatment plus camrelizumab and liposomal irinotecan in patients with RAS wild-type metastatic colorectal cancer: Cohort B of the phase II CRACK study. Quan M; Chen J; Chen Z; Hai Y; Zhou Y; Chao Q; Chen C; Li H; Wang M; Gao Y Int J Cancer; 2023 Dec; 153(11):1877-1884. PubMed ID: 37163613 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]